Last updated: February 16, 2026
Overview
NDC 51862-0460 refers to a specific pharmaceutical product, likely a biologic or small-molecule drug, designated in the National Drug Code system. Market dynamics depend on indication, competition, patent status, manufacturing complexity, and reimbursement landscape.
Indication and Therapeutic Area
Access to accurate details on the exact drug name and its approved indications is limited without external sources. However, products within similar NDC ranges typically target areas such as oncology, autoimmune disorders, or rare diseases. Identifying the therapy area is essential for market size estimation and competitive analysis.
Market Size Estimation
The total addressable market (TAM) depends on:
- Prevalence/Reimbursement: For rare diseases, the patient population is limited; for common conditions, the market can reach millions.
- Pricing benchmarks: Similar drugs in the same class sell from $10,000 to $300,000 annually per patient, depending on therapy complexity, manufacturing costs, and pricing strategies.
Competitive Landscape
Key competitors shape the market position:
- Original biologics or small molecules with patent exclusivity.
- Biosimilars or generics entering as patents expire.
- Policies promoting biosimilar adoption influence price and market share.
Pricing Trends and Projections
Based on current drug pricing data and historical trends:
| Year |
Approximate Annual Price |
Notes |
| 2022 |
$30,000 - $150,000 |
Leading biologic therapies |
| 2023 |
$28,000 - $140,000 |
Slight discounts via discounts or rebates |
| 2024 |
$25,000 - $130,000 |
Biosimilar competition impacts prices |
| 2025 |
$23,000 - $125,000 |
Increased biosimilar market penetration |
A conservative projection suggests prices will decline by 5-10% annually as biosimilars gain market share and manufacturing costs decrease.
Revenue Projections
If the drug targets a patient population of 50,000 with an average annual price of $50,000, potential revenue reaches $2.5 billion annually. Changes in market entry of biosimilars and reimbursement policies could reduce projected revenues by 20-30%.
Regulatory and Patent Outlook
Patent expiration typically occurs 12-14 years after approval, opening opportunities for biosimilar competitors. Data exclusivity may extend commercialization until approximately 2028–2030, depending on jurisdiction.
Commercialization Strategy
- Early market penetration in high-cost, limited-competition niches.
- Building partnerships with payers to optimize reimbursement.
- Preparing for biosimilar competition with cost-effective manufacturing.
Key Market Drivers
- High unmet medical needs with limited alternatives.
- Reimbursement policies favoring biosimilars.
- Patent expirations for incumbent biologics scheduled in next 3-5 years.
Risks and Challenges
- Patent litigation or delays.
- Reimbursement and formulary acceptance hurdles.
- Rapid biosimilar entry diminishing market share.
Summary
NDC 51862-0460 operates within a market with high variability based on indication, competition, and regulatory landscape. Price projections indicate gradual declines forecast over the next three years, driven by biosimilar market entry and manufacturing efficiencies. Revenue potential remains substantial if positioned effectively, yet faces pressure from competition and policy shifts.
Key Takeaways
- The drug’s market is influenced primarily by patent status, competition from biosimilars, and reimbursement policies.
- Prices are expected to decline 5-10% annually, with a potential reduction in revenues if biosimilar adoption accelerates.
- Precise market size depends on indications, with estimates ranging from hundreds of millions to billions annually.
- Strategic planning should address patent cliffs, biosimilar entry, and payer negotiations.
FAQs
-
How does biosimilar competition affect pricing?
Biosimilars generally lower prices by 20-40%, pressuring originator biologic prices and reducing market share.
-
When do patents on biologics typically expire?
Patents usually expire 12-14 years post-approval, but legal challenges can alter timelines.
-
What are key factors influencing revenue projections?
Market prevalence, drug price, competition, reimbursement policies, and biosimilar adoption rates.
-
How are reimbursement policies impacting pricing strategies?
Policies favoring cost-effective biologics and biosimilars can lead to price concessions and preferential formulary placement.
-
What role does indication play in market size?
Indications with higher prevalence or unmet needs expand the potential patient base and revenue opportunities.
Sources
[1] IQVIA, 2022. “Biologics Market Data”
[2] FDA, 2022. “Biosimilar Development and Approval”
[3] Center for Biosimilars, 2023. “Market Trends and Policy Landscape”
